Survey on target treatment for lung cancer

Four out of 10 doctors said a target agent for lung cancer would replace the conventional chemotherapeutic agents within the next five years, according to a recent survey conducted by AstraZeneca Korea (AZ Korea) which marked its seven-year launching of Iressa (gefinitib).

The survey of 162 specialists on lung cancer found 92 percent of those surveyed said Iressa may be a treatment option fo...